July 02, 2025

Body Fat Percentage Outranks BMI for Mortality

New research shows body fat percentage predicts long-term mortality more accurately than BMI, suggesting a need to revise how body composition is measured in clinical care.

Conexiant

July 02, 2025

Metabolic Syndrome Strongly Linked to Oral Diseases

New research highlights strong associations between metabolic syndrome and several oral diseases—including periodontitis, caries, and peri-implantitis—calling for more longitudinal studies to explore causation and improve patient care.

Conexiant

July 01, 2025

Stem Cell Therapy Shows T1D Reversal Potential

A new stem cell–derived islet therapy showed insulin independence, restored beta-cell function, and prevented severe hypoglycemia in type 1 diabetes, based on interim results presented at the ADA’s 85th Scientific Sessions.

Conexiant

June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Weight Loss Drugs, Heavier Implications

New guidance positions GLP-1 and GLP-1/GIP therapies as frontline options for long-term weight management—with profound implications for cardiovascular outcomes, access equity, and chronic disease care.

Conexiant

June 27, 2025

Ecnoglutide Shows Strong Weight Loss in Trial

A once-weekly GLP-1 receptor agonist, ecnoglutide, led to significant and sustained weight loss in a large study of adults with overweight or obesity, with favorable safety outcomes reported at the ADA’s 85th Scientific Sessions.

Conexiant

June 27, 2025

New Guidance Targets Risk-Based Diabetes Care

A new review outlines updated strategies for diagnosing and managing type 2 diabetes, recommending earlier use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with cardiovascular or kidney conditions.

Conexiant

June 27, 2025

Once-Monthly Drug Cuts Weight by 16%: Study

A once-monthly injectable GLP-1/GIP modulator demonstrated substantial weight loss in adults with obesity, with or without type 2 diabetes.

Conexiant